Research & Development

AgeX Therapeutics, ImStem Biotechnology sign non-binding letter of intent regarding investigational MSC candidate IMS001 for Covid-19

AgeX Therapeutics, a biotechnology company developing therapeutics for human aging and regeneration, and ImStem Biotechnology, Inc., a biopharmaceutical company developing human embryonic stem cell-derived mesenchymal stem cells (hES-MSC), today announced their signing of a non-binding letter of intent for ImStem to obtain from AgeX a non-exclusive license to use AgeX’s embryonic stem cell line ESI 053 to derive ImStem’s investigational MSC product IMS001 for development in COVID-19 as well as acute respiratory distress syndrome (ARDS) due to other causes.

Codiak BioSciences collaborates with Ragon Institute to evaluate exoVACC vaccine platform in SARS-CoV-2 and HIV

Codiak BioSciences, a company at the forefront of advancing engineered exosomes as a new class of biologic medicines, today announced that it has entered into two strategic collaborations with the Ragon Institute of MGH, MIT and Harvard to investigate the potential of its exoVACC vaccine platform in (1) SARS-CoV-2, the virus that causes Covid-19, and in (2) human immunodeficiency virus (HIV).

ISM Sensors for M800 and M300 Transmitters

METTLER TOLEDO Thornton M800 and M300 ISM process analytical instrumentation provides reliable, accurate measurements of conductivity/resistivity, pH/ORP, dissolved oxygen and dissolved ozone. On-board digital measurement and Intelligent Sensor Management (ISM) technology provide the utmost in convenience and control of sensor performance.

Gilead signs $1.97bn worth collaboration deal with Arcus Biosciences

Gilead Sciences has signed a 10-year collaboration deal worth up to $1.97bn with Arcus Biosciences to co-develop and co-commercialise the current and future cancer therapeutic product candidates in the latter's pipeline.

Merck to acquire Austrian vaccine maker Themis Bioscience

Merck has agreed to acquire Themis Bioscience, an Austrian pharma company, which is currently engaged in developing a vaccine for COVID-19. 

Shionogi to buy Tetra Therapeutics in $500m deal

Shionogi has agreed to acquire clinical-stage biotechnology company Tetra Therapeutics in a deal valued at around $500m.

Nautilus Biotechnology raises $76m in series B funding to be first to quantify human proteome

Nautilus Biotechnology, a company pioneering a high-throughput, low-cost platform for analyzing and quantifying the human proteome, today announced it has raised $76m in an oversubscribed Series B offering that closed on Monday, May 18, 2020.

Rallybio raises $145m in Series B round for developing rare disease drug candidates

Rallybio, a biopharma company based in Connecticut, has raised $145m in a Series B financing round led by Pivotal bioVenture Partners, for developing therapies for severe and rare disorders.

Boehringer Ingelheim collaborates with CDR-Life to develop antibody fragment-based therapeutics for geographic atrophy

Boehringer Ingelheim and CDR-Life announced they have entered into a collaboration and licensing agreement to research and develop antibody fragment-based therapeutics for geographic atrophy (GA).